A major problem with the use of human immunodeficiency virus type 1 (HIV-1) protease inhibitors as monotherapy has been an unacceptably high rate of emergence of resistance. To examine possible influences on the time to emergence of resistance, 24-week data were examined from five studies in which indinavir had been administered as monotherapy or as a component of combination therapy. Monotherapy data indicated a correlation between the level of HIV-1 RNA achieved and the risk of emergence of resistance: the lower the level, the lower the risk. When combination and monotherapy regimens were compared, the group receiving indinavir + lamivudine + zidovudine had a significantly lower risk of resistance, even after adjusting for the minimum HIV-1 RNA level achieved. The findings indicate that if at all possible, HIV-1-infected patients should receive combination chemotherapy to minimize the emergence of resistance to the protease inhibitor portion of the regimen. The goal of therapy should be to decrease the HIV-1 RNA load to a less-than-detectable level.
CITATION STYLE
Drusano, G. L., Bilello, J. A., Stein, D. S., Nessly, M., Meibohm, A., Emini, E. A., … Holder, D. J. (1998). Factors influencing the emergence of resistance to indinavir: Role of virologic, immunologic, and pharmacologic variables. Journal of Infectious Diseases, 178(2), 360–367. https://doi.org/10.1086/515631
Mendeley helps you to discover research relevant for your work.